Roche/ArQule Enter E2F Oncology Alliance; Roche Licensing Likely At Phase II
The partnership gives ArQule $15 mil. up-front plus additional funding for its E2F oncology program. The firm hopes to be the first to market with an E2F-targeted agent.
The partnership gives ArQule $15 mil. up-front plus additional funding for its E2F oncology program. The firm hopes to be the first to market with an E2F-targeted agent.